ONESOURCE · Healthcare
Onesource Specialty Pharma Ltd. reported revenue of ₹516 cr for July to September 2026, +37.2% on the year and +14.9% on the quarter. That is slower than this quarter has grown in recent years (+447.5% on average). It is the highest quarterly revenue in the last 12 quarters on record. Over the last four quarters revenue comes to ₹1,683 cr, +10.6% on the four before.
Operating profit (EBITDA) was ₹163 cr, a margin of 31.6%, +340 bps on the year and +419 bps on the quarter. Over the last 8 quarters the margin has ranged from 5.9% to 43.0%, averaging 27.6%. Operating costs grew +30.7% against revenue growth of +37.2%, so more of each rupee of sales reached operating profit.
Net profit was ₹57.0 cr, +470.0% on the year and +128.0% on the quarter, with earnings per share of ₹5.01. Profit before other income, one-offs and tax grew faster, at +1,700.0%; other income, one-offs or tax held the headline back. Profit over the last four quarters totals −₹2.0 cr, −105.1% on the four before.
Of the 4 companies in Healthcare that have reported Q2 FY27 so far, Onesource Specialty Pharma Ltd. ranks 1st on revenue growth; the sector median is +12.6%. Its margin moved +340 bps on the year against a sector median of −183 bps.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
A tax credit added to profit this quarter. Deferred tax recognised, or a reversal?
Profit before tax ₹53.0 cr; tax −₹4.8 cr, a credit.
Source: Quarterly statements
Core profit grew faster than reported profit: one-offs held the headline down.
Reported profit +470.0% on the year; profit before other income, exceptional items and tax +1,700.0%.
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹56.0 cr | ₹73.0 cr | ₹292 cr | ₹334 cr | ₹393 cr | ₹426 cr | ₹327 cr | ₹376 cr | ₹290 cr | ₹428 cr | ₹449 cr | ₹516 cr |
| YoY | — | — | — | +882% | +602% | +484% | +12% | +13% | −26% | +0% | +37% | +37% |
| EBITDA margin | −17.9% | −4.1% | 21.9% | 23.1% | 36.1% | 43.0% | 26.9% | 28.2% | 5.9% | 21.5% | 27.4% | 31.6% |
| Other income, % of PBT | — | — | — | — | — | 2% | — | 50% | — | — | 0% | −2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | — | — | −19% | — | — | — | — | −23% | −9% |
| Net profit | −₹130 cr | −₹40.0 cr | −₹6.0 cr | −₹42.0 cr | −₹69.0 cr | ₹98.0 cr | ₹0.0 cr | ₹10.0 cr | −₹89.0 cr | ₹5.0 cr | ₹25.0 cr | ₹57.0 cr |
| YoY | — | — | — | — | — | — | — | — | — | −95% | — | +470% |
| Core profit YoY | — | — | — | — | — | — | — | — | −437% | −102% | — | +1,700% |
| EPS | — | — | — | — | −₹6.02 | ₹8.61 | −₹0.02 | ₹0.92 | −₹7.74 | ₹0.40 | ₹2.18 | ₹5.01 |
| Flags | · | · | · | 1 | 1 | 2 | ✓ | 2 | 1 | 1 | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Onesource Specialty Pharma Ltd. reported revenue of ₹516 cr (+37.2% on the year) and net profit of ₹57.0 cr (+470.0% on the year) for July to September 2026.
Profit before other income, exceptional items and tax moved +1,700.0% on the year, against +470.0% for reported profit.
1 check raised a question: A tax credit added to profit this quarter. Deferred tax recognised, or a reversal?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.